Pemetrexed-induced scleroderma-like lesions in a lung cancer patient

Javier Sánchez-Bernal, Ignacio Rivera-Fuertes, Beatriz Aldea-Manrique, Isabel Abadías-Granado, Mariano Ara-Martín


Pemetrexed is a multi-targeted folate antagonist drug approved for the treatment of advanced and metastatic non-small cell lung carcinoma (NSCLC), and malignant pleural mesothelioma, and is known to induce cutaneous adverse reactions in approximately 20% of patients.  We report a case of an uncommon toxicity induced by pemetrexed: scleroderma-like condition of the lower extremities. This cutaneous adverse effect is often unrecognized, resulting in delayed diagnosis, which often leads to a worsening in the condition and increasing the risk of further fibrosing sequelae.

Palabras clave

Pemetrexed/adverse effects; Scleroderma, Localized/chemically induced; Antineoplastic Agents/adverse effects; Carcinoma, Non-Small-Cell Lung/therapy

Texto completo:

PDF (English)


Enlaces refback

  • No hay ningún enlace refback.

Copyright (c) 2021 Revista Chilena de Dermatología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional.